stockrow
Saturday 7 November 2026
Export VBIO’s income statement to Excel — free account
Valion Bio, Inc.
VBIO Healthcare Biotechnology
Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023.
- Revenue
- +15.9%
- EPS
- +0.91%
- Free cash flow
- −189.0%
Quarter to June 2026, against a year earlier
0.51
0.01
+2.00%
Follow VBIO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 1 | 1 | 2 | 1 | 1 | — | 0 | +13.2% | — | — | — | — | |
| Gross margin, % | — | — | — | (68.81) | (26.16) | (3.02) | 16.25 | 24.40 | 0.26 | — | (58.09) | +69.1 pt | ||||||
| EBT | — | — | — | (4) | (4) | (8) | (10) | (8) | (4) | (8) | (18) | +11.6% | ||||||
| EBT margin, % | — | — | — | (987.14) | (423.14) | (675.74) | (548.70) | (701.02) | (573.08) | 0.00 | 0.00 | +987.1 pt | ||||||
| Net income | — | 0 | — | (4) | (4) | (8) | (10) | (8) | (6) | (8) | (18) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 7,760.53 | 15,870.09 | 15,293.83 | 8,080.45 | 630.23 | 67.83 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (76,678.50) | (67,174.77) | (103,381.60) | (44,217.70) | (4,421.77) | (492.00) | (196.00) | (200.13) | (63.0%) | ||||||
| Cash flow | — | — | — | (67,812.27) | (55,859.01) | (68,280.81) | (39,168.24) | (4,561.09) | (497.83) | (151.49) | (107.80) | (63.8%) | ||||||
| Capex | — | — | — | (572.80) | 0.00 | 0.00 | (48.31) | (63.24) | 0.00 | (12.58) | (0.73) | (47.1%) | ||||||
| Free cash flow | — | — | — | (68,385.07) | (55,859.01) | (68,280.81) | (39,216.55) | (4,624.33) | (497.83) | (164.07) | (108.54) | (63.4%) | ||||||
| Book value | — | — | — | 43,810.05 | (21,719.87) | 161,479.50 | 15,941.33 | 1,918.54 | 220.43 | 523.10 | 87.91 | (52.2%) | ||||||
| Shares, m | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +208.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | 17.80 | 17.80 | 13.12 | 3.03 | 2.28 | 3.49 | — | 0.14 | 9.6 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | 1.24 | 1.53 | 0.75 | 1.08 | — | 0.02 | 0.8 | ||||||
| EV/Sales | — | — | — | 18.88 | 18.88 | 3.23 | 1.31 | (0.40) | 1.24 | — | 11.09 | 7.2 | ||||||
| EV/FCF | — | — | — | (3.98) | (3.98) | (0.72) | (0.27) | 0.05 | (0.17) | — | (0.35) | (1.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (4) | (3) | (6) | (9) | (9) | (6) | (7) | (15) | +11.4% | |||||
| Capex | — | — | — | 0 | — | — | 0 | 0 | — | (1) | 0 | +63.0% | ||||||
| Free cash flow | — | — | — | (4) | (3) | (6) | (9) | (9) | (6) | (8) | (15) | +12.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 2 | 0 | 13 | 3 | 3 | 2 | 12 | 0 | +32.1% | |||||
| Net debt | — | — | — | (2) | 0 | (12) | (3) | (3) | (2) | (6) | 5 | +17.8% | ||||||
| Shareholders’ equity | — | — | — | 2 | (1) | 13 | 4 | 4 | 3 | 24 | 12 | +47.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (274.34) | (159.78) | (102.54) | (96.56) | (149.46) | (142.01) | (52.63) | (104.96) | +221.7 pt | |||||
| ROIC | — | — | — | (3,794.79) | 0.00 | (418.13) | (1,314.84) | (2,785.47) | (524.86) | (27.46) | (61.01) | +3,767.3 pt | ||||||
| ROE | — | — | — | (695.97) | (610.57) | (140.47) | (119.47) | (228.68) | (184.96) | (93.69) | (489.30) | +602.3 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 8 | 7 | 16 | 9 | 7 | 52 | — | +45.4% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.11 | 0.18 | 0.12 | 0.13 | 0.11 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Sep 2025 · fundamentals updated 26 Oct 2026
Valion Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LABT Lakewood-Amedex Biotherapeutics Inc. | $1.3M | — (loss-making) | — | — | n/m | −420.66% (below 0%: shrinking) | — | 0.00% | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.2× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $1.3M | — (loss-making) | — | −32.27% (below 0%: shrinking) | +96.36% (above 0%: growing) | −0.17% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARTL Artelo Biosciences, Inc. | $1.2M | — (loss-making) | — | — | n/m | −879.18% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | — | 0.00% | Compare |
| VBIO Valion Bio, Inc. | $1.1M | — (loss-making) | — (loss-making) | +15.87% (above 0%: growing) | n/m | −189.01% (below 0%: shrinking) | (99.32%) | 0.00% | |
| BPTH Bio-Path Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +98.68% (above 0%: growing) | 0.00% | 0.00% | Compare |
| JAGX Jaguar Animal Health, Inc. | $950.0K | — (loss-making) | — (loss-making) | −58.88% (below 0%: shrinking) | n/m | +13.83% (above 0%: growing) | 15.84% | (620.16%) | Compare |
| Median of peers | $1.2M | — | — | −16.13% | — | +9.57% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 16 October 2026
Ownership
Directors and executive officers, together
less than 1%
3i, LP
9.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement